Get 250+ investors tailored to your startup

Invest in your industry and stage
Emails & contact info included
Excel and CSV export
Automatically

Trusted by 3,000+ startups

Top 50 Life Science VC Funds in Switzerland

Last updated: Apr 2024 A list of 50 VC funds that invest in Life science startups based in Switzerland. We rank investors based on the number of investments they made in Life science companies from Switzerland. We update this investor list every month.

Top 50 Life Science VC Funds in Switzerland

Investor	Life Science Switzerland investments
Zürcher Kantonal Bank	4
Eclosion SA	4
Foundation for Technological Innovation (FIT)	3
FAST — by GETTYLAB	2
Versant Ventures	2
Verve Ventures	2
EQT Life Sciences	2
Sunstone Life Science Ventures	2
Kinled Holding	2
VINCI CAPITAL	2
BioMedPartners	2
HTGF \| High-Tech Gruenderfonds	2
Fongit Seed Invest	2
BlueOcean Ventures	2
Rheingau Founders	2
Polytech Ventures	1
Lichtsteiner Foundation	1
Primal Capital	1
EFI Lake Geneva Ventures	1
Skyviews Life Science	1
Think.Health	1
Novartis Venture Fund	1
Rhia Ventures	1
Omega Funds	1
Renaissance	1
Recipharm Venture Fund	1
University of Zurich	1
Horizon 2020	1
Privilege Ventures	1
Bruker	1
M Ventures	1
White Loop Capital	1
Boehringer Ingelheim Venture Fund	1
LongeVC	1
VI Partners	1
Pfizer Venture Investments	1
Pfizer	1
Kurma Partners	1
SICTIC	1
HBM Healthcare Investments AG	1
FiveT Capital AG	1
Technology Fund	1
Acequia Capital (AceCap)	1
NEST pension fund	1
OCCIDENT	1
TiVentures	1
Medicxi	1
MedHoldings	1
Idinvest Partners	1
Esperante Ventures	1

Find investors that fund startups like yours. Automatically.

Our algorithm will find investors that invest in your industry, stage, and geography.

Investor list

Zürcher Kantonalbank - as an independent, incorporated public-law institution - is wholly owned by the canton of Zurich.

Investment focus

Health Care, Medical Device, Biotechnology
Seed, Series A, Funding Round
Switzerland, Japan, Spain

Portfolio highlights

Odne — Curing with light
ARTIRIA Medical — Artiria Medical empowers catheters and guidewires. We develop cutting edge technologies to revolutionize the limits of neurointerventional procedures, enabling a seamless navigation and stroke treatment.
Cultivated Biosciences — Cultivated - Creamy, dairy-free indulgence

Eclosion assists entrepreneurs with the necessary resources to bridge the gap between their laboratories and the stage where the start-up

Investment focus

Biotechnology, Pharmaceutical, Health Care
Seed, Series C, Funding Round
Switzerland

Portfolio highlights

KYLYS — KYLYS is an innovative Swiss company based in Geneva founded in March 2017. KYLYS provides people and patients with highly effective and safe products based on biomolecules.
Genkyotex — Genkyotex is dedicated to the development of innovative drugs which block enzymes that produce oxygen radicals. Such novel drugs will allow the treatment of oxygen-radical mediated acute and chronic diseases, with improved specificity, safety, and efficacy over existing antioxidants therapy, giving them a significant competitive advantage.Genkyotex targets its technology initially to the therapeutic areas of cardiovascular, metabolic and neurodegenerative diseases.
MPC Therapeutics — MPC Therapeutics develops a novel class of compounds with application in Immunotherapy and Metabolic diseases

The Foundation for Technological Innovation (FIT) has been helping startups since 1994, encourages entrepreneurship & supports innovation.

Investment focus

Health Care, Biotechnology, Information Technology
Debt Financing, Grant, Seed
Switzerland, France

Portfolio highlights

Voltiris — Voltiris filters natural sunlight to transmit it to plants and recycle the "wasted" sunlight into green electricity.
PeriVision — At Perivision, we combine artificial intelligence (AI), virtual reality (VR) and the cloud to build the next generation systems to understand visual function. Our systems improve workflow efficiency in practices and hospitals and provide deeper clinical insight into eye diseases.
SwissInspect — SwissInspect is a platform for traceable structural digital twins of infrastructure. Detect and quantify damage using state of the art ai models.

Backing engineers building awe, wonder, speed.

Investment focus

Software, Biotechnology, Health Care
Pre-Seed, Seed, Funding Round
United States, United Kingdom, France

Portfolio highlights

Yakoa — Yakoa is a NFT Fraud Detection Network.
Modelwise — Automated functional safety analysis via drag & drop. Seamless Integration. Faster Analyses. Zero Defects. More Savings.
Fluent Metal — Fluent Metal is a company that makes metal 3D printing economical, efficient, and safe.

Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
United States, Switzerland, Canada

Portfolio highlights

Nouscom — Nouscom is a next-generation immunotherapy company developing genetic cancer vaccines and oncolytic viruses..
Firefly Bio — Firefly specializes in Degrader Antibody Conjugates (DACs) which combine the unique strengths of ADCs with selective protein degraders.
Tentarix Biotherapeutics — Enabling intelligent therapies with multifunctional biologics.

Verve Ventures has invested in more than 140 science and technology startups. We support visionary and resilient entrepreneurs from day one and are a reliable partner for the entire journey. We typically invest EUR 1-3m in early as well as later stage rounds of European high tech startups.

Investment focus

Health Care, Software, Biotechnology
Series A, Seed, Series B
Switzerland, Germany, France

Portfolio highlights

Aktiia — Founded in Switzerland in May 2018 out of a passion to turn insights into action in the fight against hypertension, Aktiia’s groundbreaking medical technology provides people and their physicians comprehensive insights into blood pressure patterns that will inform the diagnosis and management of hypertension. Now available in the United Kingdom,Aktiia has received its CE Mark as a Class IIa medical device - signifying that the device has been assessed to meet high safety, health and environmental protection requirements in Europe. To learn more, visit Aktiia.com.
Groover — Groover is the best way to promote your music to blogs, radios, record labels, & Spotify playlisters. Get listened to, receive coverage & guaranteed feedback!
ARTIRIA Medical — Artiria Medical empowers catheters and guidewires. We develop cutting edge technologies to revolutionize the limits of neurointerventional procedures, enabling a seamless navigation and stroke treatment.

EQT life science develops innovative medicines, devices, and tools to address the single important thing that matters to the preservation of health. The organization believes that such opportunities add value to all stakeholders.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, The Netherlands, Switzerland

Portfolio highlights

Onera Health — Introduction to Onera sleep diagnostics and monitoring solutions
Vico Therapeutics — Vico Therapeutics is a developer of ribonucleic acid (RNA) modulating therapies for rare neurological disorders. The company discovers, develops, and delivers therapies for CNS disorders. Its initial focus is on SCA which is a subgroup of hereditary ataxia, HD which is a neurodegenerative disorder, and RTT-a neurodevelopmental disorder primarilyaffecting girls that enable clients with providing therapy for it.Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Judith van Deutekom, and Gail Mandel and it is headquartered in Leiden, The Netherlands.
Tubulis — Reimagining Antibody Drug Conjugates Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and

Sunstone Life Science Ventures is an independent European venture capital investment firm. We enable and empower life science therapeutics innovations.

Investment focus

Biotechnology, Health Care, Medical
Funding Round, Series B, Series A
Denmark, Sweden, Switzerland

Portfolio highlights

Kynexis — Kynexis is leading the way in precision medicine, focusing on the treatment of cognitive impairment associated with schizophrenia (CIAS). Explore our innovative approach and our dedication to improving the lives of millions globally.
Teitur Trophics — Teitur Trophics is a biotech company developing circular peptides for neurodegenerative diseases. The company was founded in 2020 and is headquartered in Aarhus, Denmark.
Rewind Therapeutics — Rewind Therapeutics is a developer of novel therapeutics intended to facilitate the treatment for neurological diseases.The company's first-in-class remyelinating therapeutics block inhibitory signals that prevent the expansion and migration of oligodendrocyte stem cells in order to promote effective remyelination, enabling medicalpractitioners to treat patients suffering from multiple sclerosis and other myelin-related diseases with efficacy.

Kinled was founded in 1980 to retain the investment assets of the Aisher family.In 1990, the investment focus shifted to a portfolio of early stage investments applying Kinled’s company development experience alongside the endurance and passion of family owned investments together with the strategic focus of venture capitalists.Since then,Kinled has taken 8 companies to public markets and many more to successful trade sales at significant multiples.

Investment focus

Biotechnology, Health Care, Financial Services
Seed, Funding Round, Series A
United Kingdom, United States, Switzerland

Portfolio highlights

Xapien — Xapien delivers automated insight reports on companies and individuals in minutes, so you can make informed business decisions quickly and with confidence.
OneTrust — OneTrust is a provider of privacy management and marketing compliance technology that helps organizations comply with global regulations. It automates privacy impact assessments and data inventory mapping, enforces risk remediation actions, and triggers recurring audits for continuous compliance monitoring across customer, employee, and vendor datatransfers. Its web-based software can be accessed on any device and provides a single place for a private office to collaborate with business groups, vendors, and trusted advisors managing privacy risks. The result is the ability to demonstrate privacy by design and ongoing compliance with policies, data privacy laws (GDPR, BCR, Privacy Shield), and other privacy frameworks (HITECH, ISO, GAPP, APEC).The company was founded in 2016 and is headquartered in Atlanta, Georgia.
Connect Earth — Connect Earth is an environmental data company that builds the infrastructure for climate-conscious products by aggregating and standardising environmental data and making it available through developer-first toolkits. The core product is an API solution that calculates the carbon impact of spend-based financial transactions of consumers and companies.

Vinci Capital is a leading Swiss private equity firm with over MCHF 200 under management. Since 1998 they have provided equity to over 30 Swiss technology and industrial companies to finance innovation, growth and succession-buyouts.Their investment team capitalizes on 40 years of cumulated experience in private equity and a solid operationalbackground in growth, turn-around, consolidation, IPOs and M&A situations.

Investment focus

Medical, Health Care, Biotechnology
Series A, Series B, Funding Round
Switzerland, Germany

Portfolio highlights

Anergis — Anergis, a clinical-stage biopharmaceutical company, discovers and develops allergy vaccines based on the technology of Contiguous Overlapping Peptides for ultra-fast desensitization. It offers vaccines against birch pollen, ragweed pollen, and house dust mite allergies. Francois Spertini founded Anergis in 2001. Its headquarters in Lausanne inSwitzerland.
SENSIMED — Sensimed designs, develops, and commercializes integrated micro-systems for medical devices. The company’s product portfolio includes SENSIMED Triggerfish, a product that offers an automated recoding of continuous ocular dimensional change over 24 hours. Sensimed is now focused on expanding the knowledge of how this individual data can best beused in the clinical setting to deliver customized treatment. The 24 hour profiles are being centralized on a registry together with patient and treatment information. The data is being analyzed and modeled on an ongoing basis in an attempt to identifying pathological patterns that can be used to differentiate indication, personalize treatment and assess efficacy following treatment.Sensimed was founded by Matteo Leonardi and Sacha Cerboni in August 2003 and is based in Lausanne, Switzerland.
Beqom — beqom is a Total Compensation Management Software Solution focused exclusively on managing compensation & performance for HR & Sales.

BioMedPartners is one of the leading European venture capital firms providing private equity and mezzanine financing to early- and mid-stage healthcare and human life science companies. They target the entire industry with special focus on pharmaceuticals, biotechnology, diagnostics and medical technology.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
Switzerland, Germany, France

Portfolio highlights

Tricares — TRiCares is a medical device company, devoted to developing a catheter-based valve replacement system for minimal invasive treatment of tricuspid valve regurgitation.
ImmunOs Therapeutics — ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease.
Tubulis — Reimagining Antibody Drug Conjugates Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and

The seed investor High-Tech Gründerfonds (HTGF) finances tech start-ups with growth potential and has supported more than 700 start-ups since 2005. With the launch of its fourth fund, HTGF now has about 1.4 billion euros under management. Its team of experienced investment managers and start-up experts support young companies with expertise,entrepreneurial spirit and passion. HTGF’s focus is on high-tech start-ups in the fields of digital tech, industrial tech, life sciences, chemistry and related business areas. To date, external investors have injected about 5 billion euros of capital into the HTGF portfolio via more than 2,000 follow-on financing rounds. In addition, HTGF has already successfully sold shares in more than 170 companies. Fund investors in this public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital and 45 companies from a wide range of industries. Fund investors in this public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital and 45 companies from a wide range of industries.

Investment focus

Software, Information Technology, Biotechnology
Seed, Series A, Funding Round
Germany, Switzerland, United States

Portfolio highlights

Graswald — Graswald engages in the creation of natural and digital 3D worlds for the entertainment industry.
CustomSurg — RETHINKING TRAUMA SURGERY At CustomSurg we are changing the treatment of complex bone fractures from a subjective to an objective approach, through personalized solutions.
Tubulis — Reimagining Antibody Drug Conjugates Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and

Fongit Seed Invest (FSI) is the leading Seed Money Fund of Switzerland for young technology companies. It provides smart seed capital.

Investment focus

Health Care, Medical, Biotechnology
Seed, Series A, Series B
Switzerland

Portfolio highlights

EBAMed — EBAMed SA is a Swiss startup based in Geneva whose mission is to enable safe and effective non-invasive treatments of heart arrhythmias with protontherapy. The company is currently developing a medical device to enable non-invasive heart motion imaging and real-time synchronization of the therapeutic beam. This device consists in both hardware andsoftware components and expands treatment possibilities for existing protontherapy centres, enabling them for the first time to treat heart patients.
Gmelius — Gmelius is the world's first 360 email collaboration platform designed for Gmail and your company's daily apps. Join the async movement!
Annaida Technologies — Annaida Technologies has developed a groundbreaking device, EmbryoSpin, that performs microscopic Nuclear Magnetic Resonance (“µNMR”) at a scale 10-fold better than existing technologies.

BlueOcean Ventures SA provides capital, operational and company development advisory support (mentoring, company management, divestment experience, network, negotiation support) to entrepreneurs in Switzerland. BlueOcean Ventures is based in Geneva, Switzerland.

Investment focus

Health Care, Medical, Personal Health
Series A, Seed, Series B
Switzerland, India, France

Portfolio highlights

nPloy — Simply set your filters and get matched with your dream job! Let top employers apply for you & connect with them via chat or a video call.
CyanoGuard AG — Our award-winning cyanide testing and optimizing solution is ideal for the mining, food, and medical field. It's easy to use, digital and offers real-time data.
99RetailStreet — 99RetailStreet is an eCommerce Cloudplatform for the unorganized Retail business in the developing countries. Our ecosystem targets Retailers, Distributors, and Manufacturers. 99RetailStreet provides POS solutions to Retailers, Real-Time Analytics to Manufacturers and Distributors

Rheingau Founders is a Berlin&Munich based Venture Capital firm active since 2011. Focusing on pre-seed to Series A investments in Europe, predominantly B2B in the fields of Marketplaces, Software as a Service, InsurTech, and eHealth. Rheingau targets start-ups that have the potential to sustainably disrupt existing processes and value chains.Besides the financial investment, we offer strategic support through the mentorship of our partners.

Investment focus

Software, E-Commerce, Health Care
Seed, Series A, Pre-Seed
Germany, United States, Poland

Portfolio highlights

NetBird — Wiretrustee is an open-source VPN platform built on top of WireGuard® making it easy to create secure private networks for your organization or home. It requires zero configuration effort leaving behind the hassle of opening ports, complex firewall rules, VPN gateways, and so forth.
MoleQlar — MoleQlar is a data and research-driven longevity company. It provides valuable information and offers consumers lab-tested nutritional supplements. The company focuses on functional medicine with optimized nutrition. Their product range includes Uthever NMN, Resveratrol, Betaine, Carnosine, and more. These products are aimed at lowering biologicalage and promoting health and longevity. MoleQlar also offers health tracking services. The company is certified in Germany and delivers its products EU-wide, including Switzerland.
Akhetonics — Creating the first all-optical RISC Processor

Polytech Ventures are an early stage VC firm based in Switzerland with a strong international focus. Their strategic location at EPFL in Lausanne grants us access to one of the most dynamic and recognized innovation centers in the world

Investment focus

Financial Services, FinTech, Software
Seed, Series A, Funding Round
Switzerland, United States, Spain

Portfolio highlights

yamo — Frische Bio-Kindernahrung von yamo, so lecker wie selbstgemacht und kostenlos direkt zu dir nach Hause geliefert. Jetzt probieren und profitieren.
Relai — Relai is a Bitcoin investment app that allows anyone to buy bitcoin within one minutes or set up an automated savings plan.
Earny — Payroll management built for Startups & SMEs. Swiss payroll service with no hidden fees & no hassle

Boosting health pioneers. We invest in early stage start-ups in different sectors: medtech, life science, biotech, mental health, public health, well-being.

Investment focus

Medical, Health Care, Biotechnology
Seed, Series A
Switzerland

Portfolio highlights

Microcaps — Microcaps provides a novel solution to encapsulate ingredients naturally, protect them an enhance them with high-end appearence
Healios AG — Healios CTMS provides the Digital Biomarker based technology and digital validation scales to improve and streamline research and clinical practice.
MUVON Therapeutics — Muvon Therapeutics platform helps women with urinary incontinence and treats diseases based on skeletal muscle degradation, supporting them in their commitment to living a healthy life. The company's mode of contact is by mail, phone, and physical address.

Primal Capital, an independent venture capital " incubator bait fund at ", served as the Associate than July 2012 Hiroshi was Sasaki is the venture capital fund that serves as the representative partner. Representative of Sasaki, the seed acceleration program "Incubate Camp" operated by Incubate bait fund is carried out a totalof four times of planning and management than in 2012, They have also engaged in support operations of portfolio companies. - See more at: https://www.crunchbase.com/organization/primal-capital#sthash.m2z1DCbt.dpuf

Investment focus

Software, Internet, Task Management
Seed, Funding Round, Pre-Seed
Japan, Spain, Switzerland

Portfolio highlights

Rand App — Rand is a fintech firm that offers banking services, savings, deposits, and account opening.
Degas — Degas develops solutions to improve the productivity of small-scale farmers in Africa.
xCARE — xCARE specializes in the development and commercialization phases of the pharmaceutical and medical device industries.

EFI Lake Geneva Ventures is a seed and early-stage investment strategy based in Geneva, Switzerland. Founded in 2020, our mission is to foster innovation by investing at an early stage in fast-growing innovative Swiss companies in Technology, Life Sciences and Medtech.

Investment focus

Health Care, Medical, Life Science
Seed, Pre-Seed, Series B
Switzerland, Germany

Portfolio highlights

Hylomorph — Hylomorph is a clinical-stage medical device company developing innovative materials designed to transform the biocompatibility of implantable medical devices.
FluoSphera — Fluosphera better predicts the effects of molecules through animal-free microphysiological systems, helping you to discover more efficient drugs with less adverse side effects.
Seprify — Enabling sustainable products

Skyviews Life Science is a privately held advisory company specialised in personalised health.

Investment focus

Biotechnology, Food and Beverage, Medical
Series B, Series A, Seed
United States, Switzerland, United Kingdom

Portfolio highlights

Volumina Medical — Volumina is active in the field of tissue engineering and develops injectable 3D scaffolds for the reconstruction of volumes of soft tissues (fat, muscles, glandular tissues, supporting and connective tissues) that have been lost after tumor ablation, disease, trauma, or for purely esthetically purposes.
Tropic Biosciences — We're making tropical agriculture more productive and sustainable by using cutting-edge genetic innovation. Together, we're enabling brighter futures for growers who need it most.
Vedanta Biosciences — Vedanta Biosciences is a developer of immunotherapies designed to treat immune-mediated and infectious diseases. The company's immunotherapies include a suite of proprietary assays to select pharmacologically potent strains, vast proprietary datasets from human interventional studies, and facilities for cGMP-compliant manufacturing ofrationally-defined bacterial consortia in powder form, enabling physicians to access live bacteria drug to treat autoimmune and inflammatory diseases easily.It was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Think.Health invests as a boutique risk-taker in healthcare ventures. We continuously seek innovations and disruptive business models in digital healthcare, medical technologies and health service providers,

Investment focus

Health Care, Biotechnology, Medical Device
Seed, Series A, Series B
Germany, United States, Switzerland

Portfolio highlights

Vara — Vara develops a breast cancer screening platform powered by AI for radiologists, allowing them to focus on finding cancer early. While we provide. Vara also provides remote mammography reading services to those that lack the radiologists. Vara's mission is to make affordable diagnostics available all over the world by designing machinelearning-powered workflows that users love to work with.
anvajo — Originally started at TU Dresden, anvajo can now look back on several years of innovative research and successful product development with uninterrupted growth. As part of the business expansion and ongoing team building, anvajo moved into its new headquarters in Dresden in January 2020. On 1300 m² practically all areas, including development,production and support functions are united under one roof.
Navignostics — Our mission is to identify the ideal treatment to battle each cancer patient’s disease and reduce suffering throughout their journey.At Navignostics we characterize tumors using spatial single-cell proteomics. We use our unique capabilities to identify a cancer treatment that will optimally fight each patient’s tumor. We also accelerate cancerdrug development by providing key insights into drug mechanisms and tumor features for companion diagnostic development.Our highly robust and reliable technology and our leading data analytics position us ideally to enable precision cancer diagnostics for patients and to provide services to pharma and biotech partners.This way we help people suffering from cancer by making more drugs available and by finding the right one for every patient.

Learn about the approach the Novartis Venture Fund takes to investing in innovative life science companies developing biotechnology and biopharmaceutical therapeutics that address unmet patient needs.

Investment focus

Biotechnology, Health Care, Therapeutics
Series B, Series A, Series C
United States, Switzerland, United Kingdom

Portfolio highlights

Hyku — Hyku Biosciences is developing the next generation of covalent medicines by targeting histidine, tyrosine and lysine binding pockets in disease-causing proteins.
Fore Biotherapeutics — We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics.
Hepalink — Hepalink is a manufactures ultra-pure pipeline control systems based on semiconductors and pan-semiconductor liquid circuits.

Rhia Ventures invests in reproductive healthcare solutions that empower women.

Investment focus

Health Care, Biotechnology, Women's
Seed, Series A, Pre-Seed
United States, Canada, Israel

Portfolio highlights

Eli — The women's health company providing lifelong insights from your saliva.
Contraline — Contraline is a medical device company that has developed a proprietary injectable hydrogel platform for use in reproductive and contraceptive applications. Contraline's first product, Adam, is implanted into the vas deferens through a minimally invasive, outpatient procedure and once implanted, the gel effectively blocks sperm. Adam isnon-hormonal, designed to last years, and easily reversible.
Twentyeight Health — Your birth control. Delivered to your door. Get a new or re-up existing prescriptions, free & fast deliveries and follow up messaging with doctors. $0 with insurance and starting at $16/pack without.

We aim to invest in exceptional founders and entrepreneurs and impactful products and platforms across multiple therapeutic areas.

Investment focus

Biotechnology, Health Care, Therapeutics
Series B, Series A, Series C
United States, Switzerland, United Kingdom

Portfolio highlights

ARTBIO — ARTBIO is a clinical-stage radiopharmaceutical biotechnology business that is working to create a new class of alpha radioligand medicines. ARTBIO is changing cancer care by creating a new class of alpha radioligand therapeutics (ART) and the ecosystem that supports.
Upstream Bio — Upstream Bio focuses on developing an antibody therapy for the treatment of severe asthma. Upstream Bio was founded in 2004 and was headquartered in the United States.
Bicara Therapeutics — Bicara enables access to the thriving innovation ecosystem which accelerates our development of therapies for cancer. Synergies between the Bicara teams in Boston and Bengaluru will pioneer breakthrough innovation.

Renaissance is an investment foundation for pension funds investing in Swiss SMEs. It acts as a partner of the SMEs, participating in companies within the framework of succession planning or company outsourcing and thus promotes the Swiss SME landscape by maintaining and creating jobs.The firm was founded in 1997 and is headquartered in Lausanne,Vaud.

Investment focus

Medical, Software, Health Care
Series B, Series C, Seed
Switzerland

Portfolio highlights

Anergis — Anergis, a clinical-stage biopharmaceutical company, discovers and develops allergy vaccines based on the technology of Contiguous Overlapping Peptides for ultra-fast desensitization. It offers vaccines against birch pollen, ragweed pollen, and house dust mite allergies. Francois Spertini founded Anergis in 2001. Its headquarters in Lausanne inSwitzerland.
GlassIG — It is an independent software vendor. Our aim is to provide market leading and cost effective Information Governance for everyone. At They are proud of our mission to serve and inspire our customers to establish and operate an effective Information Governance solution.
Beqom — beqom is a Total Compensation Management Software Solution focused exclusively on managing compensation & performance for HR & Sales.

Recipharm Venture Fund is part of Recipharm AB.

Investment focus

Biotechnology, Medical, Health Care
Series A, Funding Round
Sweden, Switzerland

Portfolio highlights

NewBiologix — NewBiologix operates as a technology innovation company, develops a proprietary and breakthroughDNA integration platform for the advanced engineering of human and mammaliancell lines.
Cinclus Pharma — A Swedish pharma company bringing relief to the world with the clinical stage drug candidate linaprazan glurate for gastric acid related diseases.

The University of Zurich is one of the leading research universities in Europe and offers the widest range of degree programs in Switzerland.

Investment focus

Health Care, Life Science, Biotechnology
Series A
Switzerland

Portfolio highlights

MUVON Therapeutics — Muvon Therapeutics platform helps women with urinary incontinence and treats diseases based on skeletal muscle degradation, supporting them in their commitment to living a healthy life. The company's mode of contact is by mail, phone, and physical address.

The EU framework programme for research and innovation

Investment focus

Biotechnology, Health Care, Software
Grant, Seed, Funding Round
Spain, United Kingdom, Israel

Portfolio highlights

Fairbrics — Fairbrics is developing the first synthetic fiber with a net positive impact on climate change and capable of meeting the demand of the market.
Partseeker — Partseeker is digital platform for buying and selling automotive used spare parts online.Connecting supply and demand, enriching and controlling spare parts information and thanks to our technology, we offer a smart way for consumers and professional car wrecker to sell and buy automotive used spare parts through our platforms.We provide abetter alternative to new product offering original parts, used or renewed allowing consumer to save time, money and our planet resourcesFor more information please visit www.partseeker.it
Neuron soundware — Neuron Soundware uses Artificial Intelligence and Machine Learning in combination with the analysis of sound and other physical parameters.

Privilege Ventures is the venture capital arm of Privilège Management and invest in seed and early stage companies. Geographical focus is Switzerland and the rest of Europe. Focus sectors are industrial-tech, med-tech, wearables and in general ICT.

Investment focus

Health Care, Hardware, Software
Seed, Series A, Funding Round
Switzerland, France

Portfolio highlights

Wyth — Wyth makes technologies that help humans create meaningful relationships by bringing emotions, stories and connections beyond the interface.
Smeetz — Smeetz is the future of a unified, data-driven and dynamic pricing-oriented commerce for attractions and cultural venues.
Avelo — Our mission is to save lives by bringing fast and actionable infectious disease diagnosis closer to the patient. Avelo's solution is a breath collection device. It works with existing molecular tests to detect multiple respiratory tract infections causing pneumonia

Bruker Corporation is a provider of high-performance scientific instruments and solutions for molecular and materials research, as well as for industrial and applied analysis.

Investment focus

Biotechnology, Medical, Health Care
Series A, Funding Round, Seed
United States, Switzerland

Portfolio highlights

KIYATEC — Kiyatec is a functional precision oncology company that measures the response of individual patient live cancer cells with its innovative 3D cell culture technology platform. Kiyatec works with leading biopharmaceutical companies to unlock response dynamics for investigational drug candidates for use in solid tumors.
Haystack Oncology — Haystack Oncology, an oncology company, uses the most recent circulating tumor DNA detection technology to enhance the diagnosis of minimum residual disease and provide superior therapy decision-making information.
Mercy BioAnalytics — We are making early stage cancer 100,000x easier to find using extracellular vesicles found in blood, specific to their parent cells.

Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Seed
United States, Switzerland, United Kingdom

Portfolio highlights

Nouscom — Nouscom is a next-generation immunotherapy company developing genetic cancer vaccines and oncolytic viruses..
DISCO Pharmaceuticals — DISCO Pharmaceuticals is a firm that specializes in large-scale surfaceome unlocking of cancer cells.
Polaris Electro-Optics — Polaris Electro-Optics empowers integrated photonics for communications and computation.

White Loop Capital is the first investment firm specialized in crypto-assets in France. Accompanying those who dare.

Investment focus

Finance, Software, Life Science
Seed, Pre-Seed, Funding Round
Switzerland

Portfolio highlights

Ondefy — Ondefy is building infrastructure that enables a simple access to decentralized finance. Integrate multiple DeFi services unders 1 line of code.
DeepSquare — Managed, sustainable High Performance Computing as a Service. Decentralised. Community led. Blockchain (em)powered. DeepSquare solves real-world challenges facing intense computing demand. Combining traditional as a service business with blockchain, to deliver a transparent, fair trust-less ecosystem.
Fluent — The Fluent network combines multiple tokens and offers unique market advantages compared to stablecoin competitors. Fluent is designed to be a true bridge between traditional finance and digital assets.

The Boehringer Ingelheim Venture Fund is the strategic venture fund of the Boehringer Ingelheim Corporation.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Seed
United States, Germany, Belgium

Portfolio highlights

Actym Therapeutics, Inc. — Actym Therapeutics is developing key biotech to help target intractable immune pathways in the tumor microenvironment.
smartbax — We develop novel multi-targeted, antibacterial compounds with extraordinary potency against multi-drug resistant bacteria and difficult-to-treat biofilms.
Glox Therapeutics — Developing novel precision antibiotics based on protein bacteriocins, to target Gram-negative Antimicrobial Resistant (AMR) pathogens.

With more than 30 portfolio companies across AI, pet health, ageing medicine and more, LongeVC provides venture capital for the biotech and longevity sectors.

Investment focus

Health Care, Biotechnology, Therapeutics
Funding Round, Seed, Series A
United States, Hong Kong, Switzerland

Portfolio highlights

Haut.AI — Haut.AI is SaaS platform for skin care and skin health applicaitons
AOA — AOA based in Boston, New York, and London developing cancer diagnostics in the field of women’s health.AOA is a female-led company, is committed to bringing the first accurate early-stage liquid biopsy ovarian cancer diagnostic test to market that will improve clinical practice, help reduce patient mortality and deliver cost savings to payers.
PreComb Therapeutics — functional precision medicine, oncology, cancer, discovery, organoid, predictive, ai, 3DTwin, data mining, therapy guidance, automated, immune oncology, 2curex, xilis, usz, dkfz, nct, switzerland

VI Partners are Venture Capitalists successfully financing outstanding teams and innovations in the Healthcare and Technology space since 20 years.

Investment focus

Health Care, Biotechnology, Medical Device
Series A, Series B, Series C
Switzerland, Germany, United States

Portfolio highlights

Xeltis — Xeltis is pioneering a restorative approach in cardiovascular therapy.
LeaseTeq — LeaseTeq bietet Privat- sowie Unternehmenskunden das erste komplett digitale Leasingangebot.
Unique — Try Unique Finance GPT to increase productivity by automating manual workload through AI and ChatGPT solutions.

Pfizer Venture Investments is a corporate venture capital firm that invests in areas of current or future strategic interest to Pfizer. It aims to remain at the forefront of life science advances. It identifies and invests in emerging companies that are developing transformative medicines and technologies that have the potential to enhance Pfizer’spipeline and shape the future of its industry.

Investment focus

Biotechnology, Health Care, Therapeutics
Series B, Series A, Series C
United States, United Kingdom, Switzerland

Portfolio highlights

RefleXion Medical — RefleXion is developing the first biology-guided radiotherapy system, a significant change in strategy from single tumor therapy to the ability to one day treat multiple tumors in the same treatment session in cancers that have metastasized. Currently, the RefleXion X1 machine is cleared for the delivery of stereotactic body radiotherapy (SBRT),stereotactic radiosurgery (SRS) and intensity modulated radiotherapy (IMRT). The company is also developing BgRT, which incorporates positron-emission tomography (PET) imaging data to enable tumors to continuously signal their location. The BgRT technology will synchronize these data with the linear accelerator to direct radiotherapy to tumors with subsecond latency.
Curve Therapeutics — Curve has developed an innovative screening platform that is transforming the discovery of first-in-class therapeutics. The platform allows functional screening of diverse, genetically encoded Microcycle™ libraries against a broad range of disease-associated targets that are present in their native conformation inside a mammalian cell. Curve isdeploying this platform to build a pipeline of novel cancer drugs.
ReCode Therapeutics — ReCode is the first genetic medicines platform to enable highly targeted delivery to organs, tissues and cells beyond the liver. Our pipeline of rare disease therapeutics uses optimized mRNA and gene correction with redosing capability.

Pfizer provides access to safe and effective and affordable medicines and health care services. They have a portfolio of products and medicines that support wellness and prevention, as well as treatment and cures for diseases across a broad range of therapeutic areas; and they have an industry-leading pipeline of promising new products that havethe potential to challenge some of the most feared diseases of their time, like Alzheimer's disease and cancer.

Investment focus

Biotechnology, Health Care, Pharmaceutical
Post-IPO Equity, Series A, Corporate Round
United States, Israel, France

Portfolio highlights

CellCentric — CellCentric’s primary programme targets a deubiquitinase (DUB) enzyme which is strongly associated with prostate cancer, a leading cause of mortality among men. The target modulates the androgen receptor pathway and can potentially combat the multiple resistance mechanisms seen with recently approved prostate cancer drugs such Xtandi and Zytiga.The programme also has potential clinical utility in non-small cell lung, breast and colon cancer.
AgomAb Therapeutics — AgomAb is developing molecular therapies for the regeneration of damaged tissues. Their unique agonistic monoclonal antibody molecules (“agomAbs”) stimulate molecular and cellular repair mechanisms that have the potential to restore organ function in patients with fibrotic, inflammatory, autoimmune and degenerative diseases.
EvolveImmune Therapeutics — EvolveImmune Therapeutics transforms the discovery and development of novel immunotherapies. By leveraging its proprietary in vivo target discovery platform, EvolveImmune is building a pipeline of novel therapeutic candidates against numerous targets that are expressed on multiple immune cell types. The company’s platform will generatefirst-in-class treatments for unmet needs in oncology and autoimmune diseases.

Kurma Partners is a management company based in Paris, specializing in the financing of innovation in healthcare and biotechnology, from pre-creation to development capital. Kurma Partners, which manages the Kurma Biofund I, II funds and the Kurma Diagnostics fund, is one of the main players in the financing of therapeutic and medical innovationsin Europe, particularly through links with many institutes. research and prestigious hospitals.

Investment focus

Health Care, Biotechnology, Pharmaceutical
Series A, Series B, Seed
France, Spain, Switzerland

Portfolio highlights

Poppins — Mila merges music, technology, and neuroscience to reshape therapy into a musical experience. We create musical games for children based on neurologic music therapy methods. These games are designed to address learning dissabilities like dyslexia, providing a digital treatment at home and helping identify these conditions. Behind these games, weleverage data science and new technologies to interpret learning, language, and motor performance into a cognitive score. Our goal is to improve the process for patients receiving treatment and to reaching the vast undiagnosed majority.
Shorla Pharma — Shorla Pharma is an Irish specialty pharmaceutical company. It is growing portfolio brings accessible, affordable and life-saving treatments to patients, delivering a major contribution to patient care and providing a significant clinical impact.
Vico Therapeutics — Vico Therapeutics is a developer of ribonucleic acid (RNA) modulating therapies for rare neurological disorders. The company discovers, develops, and delivers therapies for CNS disorders. Its initial focus is on SCA which is a subgroup of hereditary ataxia, HD which is a neurodegenerative disorder, and RTT-a neurodevelopmental disorder primarilyaffecting girls that enable clients with providing therapy for it.Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Judith van Deutekom, and Gail Mandel and it is headquartered in Leiden, The Netherlands.

How to Invest in Swiss Startups That Last The SICTIC Investor community helped to fund to more than 254 Swiss tech startups to date. While doing so, they learned a lot about what to watch out for and how to foster success. Read more Get your FREE angel handbook Services For Startups We invite all

Investment focus

Software, Artificial Intelligence, Information Technology
Seed, Pre-Seed, Funding Round
Switzerland, Germany, United Kingdom

Portfolio highlights

Gaia Tech — Gaia Technologies turns agricultural sidestreams into high-value ingredients for cosmetics, food, and feed manufacturers.
PeriVision — At Perivision, we combine artificial intelligence (AI), virtual reality (VR) and the cloud to build the next generation systems to understand visual function. Our systems improve workflow efficiency in practices and hospitals and provide deeper clinical insight into eye diseases.
Health Yourself — Health Yourself is making routine healthcare services available digitally and from home. So far, we are offering lab tests from home, medication subscriptions and personalised supplements for health concerns ranging from sexual health to prevention.

As a venture capital company, HBM BioVentures is invested globally in some 40 mature emerging companies in the biotechnology/human medicine, diagnostics and medical technology sectors. The primary products of HBM BioVentures' portfolio companies are either at an advanced stage of development or already available on the market. The companyfocuses on unquoted emerging companies, with two-thirds are invested in private companies that offer high value creation potential. This has enabled HBM BioVentures to carve out a unique and distinctive market position. HBM BioVentures has a broad shareholder base and is listed on the SIX Swiss Exchange (ticker: HBMN).

Investment focus

Biotechnology, Health Care, Medical
Series B, Series C, Series A
United States, Switzerland, China

Portfolio highlights

Upstream Bio — Upstream Bio focuses on developing an antibody therapy for the treatment of severe asthma. Upstream Bio was founded in 2004 and was headquartered in the United States.
Vicore Pharma — Vicore Pharma is a pharmaceutical company dedicated to developing innovative medicines for severe lung disorders. It develops drugs that act through the AT2 receptor. The company’s drug candidate C21 aims to improve the treatment of idiopathic pulmonary fibrosis, a rare disease for which C21 has been granted orphan drug designation both in the EUand the US. In addition, C21 is explored pre-clinically in a number of rare diseases where the AT2 receptor plays an important role. The company is based in Astra Zeneca’s Bioventurehub in Mölndal.
Odyssey Therapeutics — Odyssey Therapeutics is developing innovative medicines to make extraordinary leaps in outcomes for patients with cancer inflammatory diseases

FiveT is an independent alternative asset manager established in 2006. Starting in 2021, FiveT set out to finance the foundation of the hydrogen economy.

Investment focus

FinTech, Software, Health Care
Seed, Convertible Note, Initial Coin Offering
United States, Switzerland

Portfolio highlights

ZELF — Zelf is a neobank targeting Gen Z to bring financial services to where they live – in messengers. This is the lightest bank with the easiest onboarding process taking up to 60 sec to issue a card, receive and send money without leaving the messenger. We are uniquely offering AI-powered voice control over the most of financial operations, whichmakes us first voice-enabled banking for Gen Z who prefers voice interactions with their devices.
LimeWire — LimeWire develops peer-to-peer software and solutions for the file sharing industry. It offers LimeWire BASIC and LimeWire PRO, the peer-to-peer file sharing applications which connect to the Gnutella network and enables users to search for and download files through other users; and LimeWire Store, a digital media store. Limewire was founded in2000 and is based in New York, New York. The company operates as a subsidiary of Lime Group LLC.
PreComb Therapeutics — functional precision medicine, oncology, cancer, discovery, organoid, predictive, ai, 3DTwin, data mining, therapy guidance, automated, immune oncology, 2curex, xilis, usz, dkfz, nct, switzerland

Climate protection through innovative technologies. The Technology Fund offers loan guarantees to Swiss companies whose novel products contribute to a sustainable reduction in greenhouse gas emissions

Investment focus

Information Technology, Software, Biotechnology
Debt Financing, Grant, Seed
Switzerland

Portfolio highlights

FGen — FGen is a Swiss start-up company founded 2011 in Basel as a spin-off from the Department of Biosystems Science and Engineering of the ETH Zurich. As a contract reasearch organization we collaborate with partners from Biotech, Life Sciences, and Pharma in order to establish efficient bioprocesses and to develop new biopharmaceuticals.
Calopad — Calopad, awarded by the Swiss Confederation, offers a unique and the most holistic solution in pain therapy and muscle regeneration. The therapeutic deep heat of 42 degrees solves any muscle pain, muscle tension, or muscle spasms of chronic patients in the long term and in a highly efficient way through new forms of therapy. With the associatedapp, Calopad brings the physiotherapist digitally into any user's home and enables personalized all-around care in real time - utterly independent of time and place. In the future, the modular design will make it possible to combine different therapies such as heat, cold, or light with just one device, opening up the possibility of new therapeutic successes.
Selfrag — SELFRAG AG is specialized in the development of high voltage pulse power products, plants and systems for selective fragmentation of solid materials.

We are a leading early-stage investment platform. We are at the center of a global ecosystem that attracts and fuels the technical founders and product teams building the next wave of global businesses.

Investment focus

Software, Information Technology, Artificial Intelligence
Seed, Series A, Pre-Seed
United States, United Kingdom, France

Portfolio highlights

Deta — The cloud for doers and dreamers
AnySignal — AnySignal was developed to reimagine how RF capabilities are delivered for the most difficult tasks around the globe. offers complete solutions for modern aircraft, satellites, and national security that span communications, radar, navigation, and RF sensing. Current solutions are overpriced, unimaginative, and provide little end-to-end capability.To shift this paradigm, they are bringing the appropriate talent, procedures, and technologies together. They are developing communications systems for satellites, launchers, space stations, and aircraft. They provide full-stack connectivity solutions that include software modems, hardware for use in flight and on the ground, data management software, ground station integration software, and vehicle telemetry software.
Harbinger — Founded by veterans of Canoo and Faraday Future, Harbinger is an automotive company that develops EV platforms optimized for medium-duty trucks and delivery vans.

For more than 35 years, Nest, as the first ecological and ethical pension fund in Switzerland, has remained true to its guiding principle: the optimal provision for the companies affiliated with us and their employees.

Investment focus

Health Care, Biotechnology, Medical
Seed, Series A
Switzerland

Portfolio highlights

Piomic — There are about 50 million reported cases of patients suffering from hard-to-heal wounds, which has created a severe cost burden on global healthcare systems.The COMS® One Therapy System is a portable, hand-held device which incorporates the technologies for optical and magnetic stimulation, intended to promote wound healing in chronic leg andfoot ulcers.The pivotal clinical study showed that the treatment is safe, leads to accelerated wound closure, overall reduced pain and increased quality of life. The easy-to-use, single button operated device integrates smoothly into the patient’s healing journey with usage in stationary and ambulant facilities but also in patient’s home.By developing a therapy which is safe and effective we hope to set a better future for patients in need.
Comphya — CaverSTIM is a novel implantable device able to restore natural penile erection by neuromodulation.
Nagi Bioscience — Enabling small organisms testing to any lab. Unleash unique datapoints efficiently at a high-throughput rate.

Occident is an international, privately held investment company based in Zug and Munich. Our goal is to manage our own wealth in a sustainable, meaningful manner seeking to make a positive contribution to society through our investments. Venture Capital is the focus of our investment activities. We see ourselves as a long-term oriented enabler forinnovative start-ups and visionary founders. As a complementary team of experts, we are fascinated by technologically sound topics (deep tech) from the life sciences, digital and high-tech sectors with the potential to decisively improve people's lives.

Investment focus

Health Care, Medical Device, Biotechnology
Series A, Series C, Funding Round
Germany, Switzerland, Slovenia

Portfolio highlights

ReCatalyst — REvolutionizing the way we make fuel cell CATALYSTs
Tubulis — Reimagining Antibody Drug Conjugates Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and
Lunaphore — Lunaphore Technologies is a spatial biology company, building multiplex immunofluorescence & IHC solutions for discovery and immuno-oncology research

TiVenture is a seed investment fund owned by the Fondazione Centenario Banca Stato that invests in early stage companies with innovative technologies and high growth potential, principally in southern Switzerland. TiVenture is actively looking and ready to support exceptional founders and entrepreneurs developing scalable products for the globalmarket. TiVenture has a diversified portfolio of companies and is mainly active in the life science, medical, high-tech and IT sectors.

Investment focus

Software, Analytics, Renewable Energy
Seed, Series A, Funding Round
Switzerland, Italy, United States

Portfolio highlights

BigOmics — Get robust and reproducible results in a few clicks with Omics Playground: your user-friendly Omics Data Analysis Software.
Hive Power — Hive Power provides a SaaS platform to optimise your existing electrical distribution grid, both from the technical and economic points of view.
Gaia Turbine — Gaia Turbine creates a plug-and-play hydroelectric microturbine with an efficiency of over 90% that is perfect for aqueducts and the smallest necessary outflows. Gaia's two patent applications have been filed to protect the technology of the mini/micro hydroelectric turbine.

Medicxi is a life sciences-focused investment firm, originally created at Index Ventures, a leading international venture capital firm with offices in London, San Francisco, Geneva, and St. Helier (Jersey).Francesco De Rubertis joined Index at the end of 1997 to launch the firm's life sciences practice and was joined in the following yearsby three partners: Kevin Johnson, Michèle Ollier and David Grainger. Over the years, Index raised a total of twelve funds, managed with separate life sciences and technology investment teams.In 2012, Index launched sector-specific venture funds for the first time, raising separately Index Ventures VI (technology focus) and Index Life VI (life sciences focus). Global Pharma GlaxoSmithKline (NYSE: GSK) and affiliates of Johnson & Johnson (Janssen; NYSE: JNJ) both partnered with Index by investing in Index Life VI. This was a key step in the path towards the founding of Medicxi as an independent venture firm. (read here)Medicxi started its operations in February 2016, with offices in London, Geneva and St Helier (Jersey). Giuseppe Zocco, co-founder of Index Ventures, joined Medicxi shortly thereafter to help build the firm’s late-stage platform and lead the launch of its first Medicxi Growth fund, MG1. (read here)Currently, the firm is actively investing its 2 most recent funds, Medicxi Ventures 1 (focus on early-stage companies) and Medicxi Growth 1 (focus on later stage companies), in addition to managing the entire portfolio of all prior Index life sciences investments.The firm is led by its five co-founders and Partners: Francesco, Kevin, Michèle, David and Giuseppe. Over the years, the five of them have collectively been involved in starting over seventy companies in several countries.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Seed
United States, United Kingdom, The Netherlands

Portfolio highlights

D3 Bio — D3 Bio is a globally focused biotechnology company focusing on developing and registration of innovative medicines in oncology and immunology. At D3 Bio, our new medicine development approach is fundamentally differentiated. We do not just only start with science in the lab. First, we pinpoint the greatest unmet patient and market needs – whereexisting standard-of-care approaches yield unsatisfactory clinical outcomes. Then we take those insights into the lab to guide the identification of fit for purpose science and technology and define our drug development path.
ProfoundBio — ProfoundBio is an oncology biotherapeutics company focused on the development of novel antibody-based therapeutics with curative potential for patients with cancer.
Alys Pharmaceuticals — Alys Pharmaceuticals engages in immuno-dermatology services. The company is reshaping the treatment landscape through advanced scientific innovations and a strong research and development-focused multi-platform pipeline. Alys emerged as a result of the strategic aggregation of 6 asset-centric companies backed by Medicxi.

MedHoldings operates as a venture capital and private equity firm. MedHoldings focuses primarily on development and late-stage medtech ventures in Switzerland, Europe, and emerging markets. The company conducts its business in Switzerland.

Investment focus

Medical, Health Care, Life Science
Series A
Switzerland

Portfolio highlights

Abionic — Abionic SA is ideally positioned at the boundaries of medical technology, biotechnology and nanotechnology. As a spin-off from EPFL (Swiss Federal Institute of Technology Lausanne, Switzerland), Abionic uses these highly advanced technologies to provide the medical profession with a novel diagnostic tool designed to give patients personal allergyprofiles. Abionic aims to become an important international player in the field of personalized medicine, in particular in allergy detection.Abionic SA is a certified ISO 9001/13485 company, including research, development and commercialization of in vitro diagnostic devices for allergies detection. The standard ISO 13485 specifies requirements for a quality management system where an organization has to demonstrate its ability to provide medical devices and related services that consistently meet customer and regulatory requirements.Abionic SA is a privately owned high-tech company and is strongly supported by the Swiss Federal Institute of Technology of Lausanne (EPFL), The Canton of Vaud and Venturelab.Abionic was founded by former scientists from the biomedical optics laboratory (LOB) at EPFL. Its headquarters are located in Lausanne, Switzerland.Abionic appreciates the support it has received from:

Idinvest Partners is a pan-European private equity manager focused on the low and middle-market segments. With over 6 billion euros under management, the company has developed several complementary areas of expertise, including equity investments in buyout deals focusing on both mid-size as well as young innovative European companies; primaryinvestments in European private equity funds focusing primarily on the middle market segment; secondary investments; mezzanine investments in Europe; and private equity consulting.Idinvest Partners’ recent success stories include Criteo, Clear2Pay, Meetic, Prosensa, Converteam, Kwik Fit, Lastminute.com, Dailymotion, Deezer, Talend, Synthesio, Menlook, Vestiaire Collective, Pretty Simple, Curse.com, Withings, Kantox, Secret Escapes, Happn, Peakon, Dayuse, Botify, Financefox, Azalead and many more.

Investment focus

Biotechnology, Software, Health Care
Series B, Series A, Funding Round
France, United States, Spain

Portfolio highlights

Corti — Corti offers a digital assistant, augmenting medics in improving patient outcomes and internal performance.
Coave Therapeutics — Coave Therapeutics is active in the field of gene therapies in rare ocular and CNS (Central Nervous System) diseases.
BreezoMeter — BreezoMeter offers personalized air quality & pollen data as well as active fire alerts with worldwide coverage & accuracy down to the street level.

A corporate venture investment company focussed on investing in mid to late stage clinical stage therapeutics development companies in North America and Europe

Investment focus

Biotechnology, Health Care, Medical
Funding Round, Series A, Series B
United Kingdom, Switzerland

Portfolio highlights

Arquer Diagnostics — UroSens Ltd is based at the Babraham Research Campus, Cambridge, UK, and on the North East Business and Innovation Centre, Sunderland, UK.
Versantis — Versantis is a Swiss pharmaceutical company, Spin-off of ETH Zurich, developing a new generation of medicines and diagnostics to revolutionize the care of patients with liver disease. Embracing lifesaving and preventive therapies, Versantis aims to answer the unmet medical need of millions of people worldwide. Its lead candidate, VS-01, iscurrently at preclinical stage and has the potential to be the first drug for acute liver disease simultaneously supporting multiple failing organs. VS-01 targets 3 rare indications and received an Orphan Drug Designation in ALF. In addition, Versantis’ pipeline promises to improve patients’ outcome in other medical fields; VS-02 and VS-03 are developed for chronic liver diseases and for the treatment of drug intoxications, both representing large market opportunities and significant upsides for Versantis.
Amlo Biosciences — From ground-breaking research to revolutionary prognostics and diagnostics AMLo Biosciences is translating ground-breaking research in cancer biomarkers int ...

Investors by industry

Media (entertainment)

EdTech

Consumer

Climate